Shattuck Labs, Inc. Retained Earnings
Shattuck Labs, Inc. (STTK) had Retained Earnings of -$460.45 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$460.45M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$445.30M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$430.53M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$417.94M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$460.45M 10-Q · filed 2026-08-11 |
| 2026-03-31 | -$445.30M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$430.53M 10-Q · filed 2026-08-11 |
| 2025-09-30 | -$417.94M 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$407.88M 10-Q · filed 2025-08-14 |
| 2025-03-31 | -$395.42M 10-Q · filed 2025-05-01 |
| 2024-12-31 | -$381.72M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$363.04M 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$346.37M 10-Q · filed 2024-08-01 |
| 2024-03-31 | -$324.81M 10-Q · filed 2024-05-02 |
| 2023-12-31 | -$306.31M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$288.62M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$261.08M 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$239.74M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$219.01M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$193.60M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$168.97M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$141.59M 10-Q · filed 2022-05-12 |
| 2021-12-31 | -$117.07M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$124.91M 10-Q · filed 2021-11-09 |
| 2021-06-30 | -$107.50M 10-Q · filed 2021-08-12 |
| 2021-03-31 | -$83.91M 10-Q · filed 2021-05-10 |
| 2020-12-31 | -$72.09M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$60.08M 10-Q · filed 2020-11-13 |
| 2019-12-31 | -$35.49M 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |